At PureTech, we are creating new categories of therapeutics derived from our deep understanding of the Brain-Immune-Gut (BIG) axis

Psychosis, negative symptoms, and cognitive impairments in schizophrenia, Alzheimer’s disease and other mental illnesses remain poorly treated

There are approximately 2.7M living with schizophrenia and 5.7M living with Alzheimer's in the US

Antipsychotics are the mainstay therapy targeting dopamine pathways, however with no new treatment mechanism in 60 years, the prognosis for patients remain poor

Cuurent antipsychotics only address psychosis (positive symptoms) and are associated with serious side effects such as sedation, extrapyramidal side effects such as motor rigidity, tremors and slurred speech, and weight gain 

A class of medicines (M1/M4 agonists) that showed enormous potential in clinical studies was never developed due to tolerability issues.

We asked “What if you you could selectively target M1/M4 receptors in the central nervous system without affecting the peripheral tissues where most side effects occur?”

Karuna is developing a potentially first-in-class oral modulator of muscarinic receptors

KarXT combines xanomeline, a novel muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that acts peripherally and does not measurably cross the blood-brain barrier

MORE >

Can we develop an anti-viral that works by boosting the immune system?

A new approach in targeting the mTOR pathway by selectively targeting TORC1, linked to increased lifespan and other beneficial effects. We are focusing initially on the reduction of RTIs in elderly individuals at increased risk of RTI related morbidity and mortality. Our selective mTORC1 inhibition program has potential in other aging related indications including cognition, cardiovascular and cancer.

MORE >

The human microbiome is increasingly implicated in various immune-mediated disease states

Vedanta has discovered specific bacteria that induce T regs (which form the basis for Vedanta's IBD and food allergy candidates) and CD8+ cells (which form the basis for Vedanta's IO candidate)

Many existing IBD interventions are limited by toxicities and systemic immune suppression

Food Allergy treatment today primarily centers around allergen avoidance, and new immunotherapies focused on desensitization may note prove cost-effective relative to this approach

Checkpoint Inhibitors are only effective in 20-30% of patients

C. difficile is typically treated using antibiotics (damage the microbiome and leave patients vulnerable to re-infection) or FMT (uncharacterized safety issues)

What if we could treat immune and infectious disease by mimicking the ways in which the gut microbiota maintains a healthy immune system in humans?

Vedanta is developing a potentially new category of therapies based on a rationally-defined consortia of human microbiome-derived bacteria

Defined consortia have potential to shift microbiota, stimulate immune responses, and provide colonization resistance against infectious pathogens

Clinical results for VE303, VE800, and VE416 are anticipated in 2020

Foundational patents issued in key territories 

MORE >

Low five year survival rate for many aggressive solid tumors, including metastatic pancreatic and colorectal cancer, and metastatic cholangiocarcinoma

Many aggressive solid tumors do not benefit from approved immuno-oncology agents

Low response rate to immunotherapy

"Cold" tumors lack cancer-killing immune cells

Finding targets that suppress multiple immunosuppressive pathways simultaneously has proven challenging, and combination therapies are limited by toxicity

Can we target the immunosuppressive cells that solid, malignant tumors establish to ward off the body’s natural defenses?

Developing first-in-class fully human mAbs targeting immunologically silent tumors with galectin-9 and immunosuppressive γδ T cells that mediate immunosuppression through multiple mechanisms and has the potential for single efficacy as well as combinations.

MORE >>